FRONTEO : Established "Novel Targets Library" to introduce target genes with novelty and high potential

2024.04.08Press release

--To the press -

Established "Novel Targets Library" to introduce target genes with novelty and high potential Utilizing a new method to visualize target genes with high potential for drug discovery, "hypertension" is released as the first step

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Growth)

　FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President and CEO: Masahiro Morimoto, hereinafter referred to as FRONTEO) will introduce target genes with novelty and high potential as part of FRONTEO's introduction of its unique technology.Novel Targets LibraryWe are pleased to announce that we have published a new target gene for ``hypertension'' as the first step. We plan to gradually add more diseases in the future.

　Novel Targets Library is a new technology that uses the in-house developed AI "KIBIT" to plot genes related to diseases based on their relevance and causation, and visualize target genes with high potential as drug discovery targets. We utilize an analysis method developed in This method is expected to further improve the accuracy and efficiency of drug discovery target discovery in "Drug Discovery AI Factory," an AI drug discovery support service that supports pharmaceutical companies aiming for innovative first-in-class drug discovery. .

Novel Targets Libraryhttps://lifescience.fronteo.com/ddaif-sp/novel-targets-library

　KIBIT uses its unique natural language processing technology to analyze the vast amount of article information listed in PubMed* and is able to find genes related to diseases. Genes that are thought to be related to a disease include causative genes that cause the onset of the disease and responsive genes that are affected by the onset of the disease. Genes that are highly related to a disease and are also highly causative can be said to be target genes that can be expected to have therapeutic effects. KIBIT analyzes each gene, and genes in the upper right area (see the figure below) that have high scores for both disease relevance and causation are considered to have high potential as drug discovery targets.
* A biomedical article database operated by the National Center for Biological Sciences Information of the U.S. National Library of Medicine.https://pubmed.ncbi.nlm.nih.gov/

　Some of the genes plotted in this area include target genes for which there are currently no papers reporting a relationship with the disease, or only a very small number of papers, even if searched on PubMed. By screening these genes, it is possible to discover highly novel target genes that are unknown to drug discovery researchers and difficult to detect using conventional approaches.

　FRONTEO will contribute to improving the quality of medical care and patients' QOL by supporting pharmaceutical companies aiming for innovative drug discovery.

■About Drug Discovery AI Factory　URL:https://lifescience.fronteo.com/
　Drug Discovery AI Factory (DDAIF) is a service that utilizes FRONTEO's in-house developed AI specialized in hypothesis generation for drug research and development to support efficiency, acceleration, and success rate improvement of drug discovery. Hypotheses in drug research and development predict mechanisms based on the relationship between target molecules and diseases, and play an extremely important role in various phases from target discovery, which is the most upstream stage of development, to clinical trials and market launch. That's one. At DDAIF, we generate and propose hypotheses based on evidence, including the search and evaluation of highly novel target molecules and biomarkers, elucidation of mechanisms, proposal of indications, and evaluation of seeds, according to customer needs.

■ About FRONTEO　URL:https://www.fronteo.com/
　FRONTEO is a data analysis company that provides various AI solutions and services using the in-house developed AI engine "KIBIT". Based on the philosophy of "providing solutions that do not overlook risks and opportunities buried in records and realizing fairness in the information society," extract meaningful and important information from vast amounts of text data and complex networks. Our strengths are natural language processing and network analysis technologies that support advanced judgments by experts.We are developing businesses in the areas of legal tech AI, business intelligence, life science AI, and economic security, and contributing to solving various corporate and social issues. Founded in August 2003, listed on Tokyo Stock Exchange Mothers (currently Tokyo Stock Exchange Growth) on June 8, 2007.The company operates in Japan, the United States, South Korea, and Taiwan.Acquisition of first-class medical device manufacturing and sales business license, notification of controlled medical device sales business.Capital 6 thousand yen (as of March 26, 3,042,317).

*FRONTEO, KIBIT, and Drug Discovery AI Factory are registered trademarks of FRONTEO in Japan.

PR Department, FRONTEO, Inc.
Email: [e-mail]
Life Science AI Business Department, FRONTEO, Inc.
https://lifescience.fronteo.com/contact